UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo AB (publ) (STO:ORX) informs that the CEO of Orexo, Nikolaj Sørensen, today has sent a letter to all shareholders of the company. The letter provides an update on the commercialization of Zubsolv® and the sales progress in the U.S. market as well as a general business update. The letter is also available on the company’s home page at www.orexo.com.
About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com.
For information about ZUBSOLV and opioid dependence, please visit www.zubsolv.com and www.outthemonster.com
This information was brought to you by Cision http://news.cision.com
Contacts
Orexo
Nikolaj Sørensen
President and CEO
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com
Help employers find you! Check out all the jobs and post your resume.
